Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 48

1.

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK.

Lancet. 2001 Sep 22;358(9286):958-65.

PMID:
11583749
[PubMed - indexed for MEDLINE]
2.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

PMID:
15461877
[PubMed - indexed for MEDLINE]
Free Article
3.

Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C.

Keating GM, Curran MP.

Drugs. 2003;63(7):701-30. Review.

PMID:
12656650
[PubMed - indexed for MEDLINE]
4.

Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C.

Baker DE.

Rev Gastroenterol Disord. 2003 Spring;3(2):93-109. Review.

PMID:
12776006
[PubMed - indexed for MEDLINE]
5.

Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b.

Foster GR.

Drugs. 2010;70(2):147-65. doi: 10.2165/11531990-000000000-00000. Review.

PMID:
20108989
[PubMed - indexed for MEDLINE]
6.
7.

Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.

Hartwell D, Jones J, Baxter L, Shepherd J.

Health Technol Assess. 2011 Apr;15(17):i-xii, 1-210. doi: 10.3310/hta15170. Review.

PMID:
21473834
[PubMed - indexed for MEDLINE]
Free Article
8.

Management of chronic hepatitis C patients who have relapsed or not responded to pegylated interferon alfa plus ribavirin.

Dieterich DT, Rizzetto M, Manns MP.

J Viral Hepat. 2009 Dec;16(12):833-43. doi: 10.1111/j.1365-2893.2009.01218.x. Review.

PMID:
19889142
[PubMed - indexed for MEDLINE]
9.

Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naïve patients with hepatitis C virus infection: meta-analysis of randomized controlled trials.

Singal AK, Jampana SC, Anand BS.

Dig Dis Sci. 2011 Aug;56(8):2221-6. doi: 10.1007/s10620-011-1765-0. Epub 2011 Jun 4. Review.

PMID:
21643737
[PubMed - indexed for MEDLINE]
10.

Treatment with peginterferon plus ribavirin vs. interferon plus ribavirin for 48 weeks in Chinese patients with chronic hepatitis C.

Zhao SH, Chu YL, Cheng DX, Waqar AB, Yu Q, Yang PH, Xue X, Yang HJ, Liu EQ.

Int J Clin Pract. 2009 Sep;63(9):1334-9. doi: 10.1111/j.1742-1241.2009.02082.x. Review.

PMID:
19691617
[PubMed - indexed for MEDLINE]
11.

Pharmacotherapy of chronic hepatitis C virus infection - the IDEAL trial: '2b or not 2b (= 2a), that is the question'.

Toyoda H, Kumada T.

Expert Opin Pharmacother. 2009 Dec;10(17):2845-57. doi: 10.1517/14656560903321521. Review.

PMID:
19891593
[PubMed - indexed for MEDLINE]
12.

Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C.

Perry CM.

Drugs. 2012 Mar 26;72(5):619-41. doi: 10.2165/11208370-000000000-00000. Review.

PMID:
22439668
[PubMed - indexed for MEDLINE]
13.

Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group.

Keeffe EB, Hollinger FB.

Hepatology. 1997 Sep;26(3 Suppl 1):101S-107S. Review.

PMID:
9305673
[PubMed - indexed for MEDLINE]
14.

Reducing treatment duration in patients infected with hepatitis C genotype 1: any need for further studies?

Craxì A.

Antivir Ther. 2009;14(8):1045-9. doi: 10.3851/IMP1428. Review.

PMID:
20032534
[PubMed - indexed for MEDLINE]
15.

A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C.

Sagmeister M, Wong JB, Mullhaupt B, Renner EL.

Eur J Gastroenterol Hepatol. 2001 May;13(5):483-8. Review.

PMID:
11396525
[PubMed - indexed for MEDLINE]
16.

[Hepatitis C: which strategy in case of treatment failure ?].

Bronowicki JP, Larrey D, Tran A, Perronne C, Denis J, Cadranel JF, Trépo C.

Gastroenterol Clin Biol. 2008 Mar;32(3 Pt 2):S109-16. doi: 10.1016/S0399-8320(08)73273-1. Review. French.

PMID:
18675180
[PubMed - indexed for MEDLINE]
Free Article
17.

Boceprevir: a review of its use in the management of chronic hepatitis C genotype 1 infection.

Garnock-Jones KP.

Drugs. 2012 Dec 24;72(18):2431-56. doi: 10.2165/11209560-000000000-00000. Review.

PMID:
23231027
[PubMed - indexed for MEDLINE]
18.

Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV - the role of epoetin, G-CSF and novel agents.

Mac Nicholas R, Norris S.

Aliment Pharmacol Ther. 2010 May;31(9):929-37. doi: 10.1111/j.1365-2036.2010.04269.x. Epub 2010 Feb 18. Review.

PMID:
20175767
[PubMed - indexed for MEDLINE]
19.

Antiviral therapy for patients with chronic hepatitis C.

Heathcote J.

Semin Liver Dis. 2000;20(2):185-99. Review.

PMID:
10946423
[PubMed - indexed for MEDLINE]
20.

Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C.

Perry CM, Jarvis B.

Drugs. 2001;61(15):2263-88. Review.

PMID:
11772139
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk